Home
/
Alcides articles
Home
News
General News
General Crypto News
Facebook
Amazon
Apple
Netflix
Google
Insights
Market Performance
About us
About us
Terms and Conditions
Privacy Policy
Contact us
My Account
Buy the Dip on These 2 Cybersecurity Stocks
CRWD | 1.82%
S | -4.99%
Is Amazon Becoming a Wireless Provider?
AMZN | 0.91%
ARK ETF Sets Its Sights on AI and Software, Seeing Potential in Tesla, Nvidia
ARKK | 1.06%
TSLA | 1.70%
NVDA | -0.40%
MongoDB's Impressive Ascent: A Closer Look into MongoDB's Growth
MDB | 3.26%
Netflix's Password-Sharing Crackdown May Bolster Stock Performance
NFLX | 0.77%
2 Falling Knives to Avoid
COIN | -9.06%
LCID | -0.15%
What the heck do we do with NVIDIA (NVDA) now?
NVDA | -0.40%
About the Author
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.
Neuralink presents LINK V0.9
Elon Musk delivers on his promise.
By Alcides |
2 years ago
TSLA
Provention Bio's novel diabetes treatment
Under looked biotech company might be near tipping point
By Alcides |
2 years ago
PRVB
Novo Nordisk in the expanding market of diabetes care
The Danish multinational offers an exciting growth opportunity.
By Alcides |
2 years ago
NVO
The COVID-19 vaccine market will not be a winner-takes-all
The US government has selected three vaccine candidates to fund their Phase 3 trials through Operation Warp Speed.
By Alcides |
2 years ago
AZN
BNTX
MRNA
PFE
Load More